Precision Medicine in Central Nervous System Drug Development

Precision medicine, which has been pioneered by the field of oncology, aims to target the right treatments to the right patients at the right time. Recent advances in genomics and imaging, as well as the discovery of other biomarkers, have enabled precision medicine to become a more viable treatment option. The next frontier in this type of medicine may be in the treatment of central nervous system disorders.

This webinar evaluates the following:

  • What lessons can we learn from the use of precision medicine in oncology?

  • How has a recent clinical precision medicine application shown potential in the treatment of Alzheimer’s?

  • What questions should you ask before you add a new biomarker to your clinical trial?

  • What are the pros and cons of using biomarkers as surrogate endpoints?

Participants also had the opportunity to ask questions during and after the discussion. View the webinar playback to explore the latest findings in the application of precision medicine to treat disorders in the central nervous system.

Additionally, when you sign-up to view the presentation you'll receive a notification when the white paper becomes available.


WATCH THE
WEBINAR

WEBINAR PRESENTER:

Company team

Daniel Klamer, MS, Ph.D., MBA 
VP, Business Development & Scientific Strategy

Anavex Life Sciences Corporation

Dr. Daniel Klamer, has more than 15 years of experience in neuroscience and the orphan disease space, with acquisition, partnering and R&D experience in Europe and the U.S. Prior to Anavex, he worked at Retrophin and Neurosearch Sweden. At Neurosearch Sweden, Dr. Klamer led and evaluated multiple discovery-phase neuropharmacological research products with an emphasis on strategic evaluation of preclinical and clinical development.

Dr. Klamer earned his Ph.D. in Pharmacology at The Sahlgrenska Academy at the University of Gothenburg, Sweden, his MBA at Fordham Gabelli School of Business, and his Post-Doctoral training at the Department of Psychiatry, Yale University School of Medicine. In addition, Dr. Klamer holds a position as an Associate Professor at the Department of Pharmacology at The Sahlgrenska Academy at the University of Gothenburg. Learn more.


IN COLLABORATION WITH: